Dare Bioscience (DARE)
(Delayed Data from NSDQ)
$0.42 USD
-0.01 (-3.01%)
Updated May 28, 2024 09:53 AM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Dare Bioscience, Inc. [DARE]
Reports for Purchase
Showing records 61 - 80 ( 212 total )
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways from Panels & Fireside Chats at Our 34th Annual ROTH Conference
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Reasons to Sit Down with These Healthcare/Biotech Management
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Rx for Portfolios, Part 3: Commercial Launches Worth Keeping an Eye On
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Cash Balance and 2022 Catalysts For Our Biotech Coverage Universe
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
BV-1 (Xaciato) Approval Marks a Best-in-Class Start to Life as a Commercial-Stage Company; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
FDA Approval A Positive For Women''s Health Pipeline- Reiterate Buy $11 PT
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Companies With YE2021 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Raise Cash as Share Count Goes from 50 to 71M
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
3Q2021 Update - DARE-BV1 PDUFA Dec 7th & Deets on Commercial Plans After
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on BV-1 Decision and Commercialization Strategy Reveal; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1/2 DARE-VVA1 Study for Vaginal Atrophy Initiated, Data in 2022
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
2Q2021 Update - Very Productive 1H2021 With 2H2021 Focus Being DARE-BV1
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Busy 2Q Paves the Way for Dare?s Potential First Approval in 4Q; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D